AOD-9604 · Research brief
Best Peptides for Fat Loss — Research Compounds Compared
Short answer
The compound sitting at the top of most best peptides for fat loss lists isn't actually a peptide. 5-Amino-1MQ is a small-molecule methylquinolinium that inhibits nicotinamide N-methyltransferase (NNMT), the enzyme that methylates nicotinamide inside fat cells and, in doing so, consumes raw material the cell would otherwise route toward NAD+ synthesis.
Key takeaways
- The best peptides for fat loss split into three mechanism families, and compounds from different families are not substitutes for one another in a research model.
- 5-Amino-1MQ is a small-molecule NNMT inhibitor, not a peptide, despite appearing on nearly every peptide fat-loss ranking published.
- AOD-9604 corresponds to amino acids 177–191 of human growth hormone, and its larger human obesity trial did not separate from placebo on weight endpoints.
- MOTS-c is a 16-amino-acid mitochondrial-derived peptide characterised in Cell Metabolism in 2015 as an AMPK activator, with evidence still confined to preclinical models.
- Net peptide content sits below gross vial mass because of TFA counterion and residual water, so two 10mg vials from different suppliers are rarely equivalent.
- Lyophilised peptides are stored at −20°C and protected from light, while reconstituted solution is held at 2–8°C and degrades through freeze-thaw cycling and oxidation.
The compound sitting at the top of most best peptides for fat loss lists isn't actually a peptide. 5-Amino-1MQ is a small-molecule methylquinolinium that inhibits nicotinamide N-methyltransferase (NNMT), the enzyme that methylates nicotinamide inside fat cells and, in doing so, consumes raw material the cell would otherwise route toward NAD+ synthesis. It gets filed next to peptides because it shares the same research audience, not because it shares the same chemistry.
That distinction matters more than any potency ranking. We synthesise and supply research-grade material in small batches, and our team reviews the analytical data on every lot before it reaches a shelf. What we've watched over the past several years is a category that gets louder each season while the underlying evidence base moves slowly. So the useful question isn't which compound is strongest. It's which compound has real data behind the mechanism, and whether the material in the vial is good enough to reproduce it.
What are the best peptides for fat loss in research settings?
The best peptides for fat loss studied in laboratory and preclinical research fall into three mechanism families: growth hormone secretagogues (tesamorelin, modified GRF 1-29, ipamorelin), direct lipolytic hGH fragments (AOD-9604, the 177–191 sequence), and metabolic signalling compounds (MOTS-c, 5-Amino-1MQ). Mechanism class, not marketing language, decides which research model a compound actually suits.
The common oversimplification is that these compounds are interchangeable versions of the same idea. They're not. A GHRH analogue acts upstream on pituitary somatotrophs, an hGH fragment acts downstream on the adipocyte itself, and the two generate entirely different readouts in the same experimental model. Ranking the best peptides for fat loss by milligram strength tells you nothing useful. What follows covers the three mechanism families, where the published human evidence stops for each, and the purity and handling variables that quietly decide whether any of it is reproducible.
Three mechanism families, three completely different experiments
Every compound in this category acts through one of three routes, and they aren't variations on a theme. Choosing between them is a design decision, not a preference.
Growth hormone secretagogues act on the pituitary. Tesamorelin is a synthetic analogue of growth hormone-releasing hormone (GHRH), stabilised with a trans-3-hexenoyl group at the N-terminus so it resists enzymatic degradation longer than the native sequence. Modified GRF 1-29, catalogued as CJC-1295 without DAC, is a 29-amino-acid GHRH analogue with a short reported plasma half-life of roughly 30 minutes, producing a pulse rather than a plateau. Ipamorelin is a pentapeptide agonist at the growth hormone secretagogue receptor (GHS-R1a), the ghrelin receptor, and preclinical characterisation describes it as selective, with limited effect on cortisol and prolactin relative to older secretagogues. Growth hormone itself raises hormone-sensitive lipase activity in adipose tissue and suppresses lipoprotein lipase-mediated fat uptake, with visceral depots responding more than subcutaneous ones.
Direct lipolytic fragments skip the pituitary entirely. AOD-9604 corresponds to amino acids 177–191 at the C-terminus of human growth hormone, the region rodent work associated with lipolytic and anti-lipogenic activity without the IGF-1 elevation seen with the full 191-amino-acid molecule.
Metabolic signalling compounds work at the cell's energy sensor rather than the endocrine axis.
In our experience, poorly designed studies usually go wrong right here. Pairing a secretagogue with a direct fragment in the same arm makes the result uninterpretable, because the two act on different tissues at different points in the cascade.
Where the published evidence actually stops
Human evidence across this category varies enormously, and it doesn't track with popularity. Tesamorelin has the strongest clinical record by a wide margin, while several of the most heavily marketed compounds have never been through a human body-composition trial at all.
Tesamorelin was evaluated in multicentre randomised, placebo-controlled trials, including work published in the New England Journal of Medicine in 2007, which reported a significant reduction in visceral adipose tissue in patients with HIV-associated lipodystrophy. A branded prescription formulation exists for that narrow indication. That authorisation belongs to a finished drug product manufactured under pharmaceutical controls; research-grade tesamorelin is not that product and is not a drug.
AOD-9604 is the cautionary tale. Rodent data were encouraging enough to carry the fragment into human obesity studies, and the larger, longer trial reported by its developer did not separate meaningfully from placebo on weight endpoints. The mechanism was never disproven. The effect size simply didn't survive translation.
MOTS-c, a 16-amino-acid peptide encoded within the mitochondrial 12S rRNA gene, was characterised in Cell Metabolism in 2015 as an activator of AMP-activated protein kinase (AMPK), the switch that shifts cells from storage toward substrate oxidation. 5-Amino-1MQ has published preclinical data in diet-induced obese mouse models reporting reduced fat mass. Both remain rodent-stage compounds, which is a legitimate reason to study them and not a reason to describe them as fat-loss agents.
Growth hormone secretagogues share a separate structural problem: most supporting data measure serum growth hormone and IGF-1, which are surrogate markers. A compound can raise a growth hormone pulse reliably and still move a body-composition endpoint very little.
Purity, net peptide content, and the paperwork that proves both
A vial labelled 10mg rarely contains 10mg of peptide, and that single fact undermines most milligram-for-milligram comparisons in this category. Synthetic peptides are typically isolated as salts, most often trifluoroacetate (TFA), and the counterion plus residual water contributes real mass to the fill weight.
Net peptide content, measured by amino acid analysis or nitrogen determination, sits meaningfully below gross vial mass. Two suppliers can both be entirely honest and still ship different quantities of active sequence under an identical label. Purity by HPLC (high-performance liquid chromatography) tells you what proportion of the peptide present is the correct sequence. It says nothing about how much peptide is there. Both numbers matter, alongside mass spectrometry confirming the observed molecular weight matches the intended sequence.
Physical state is the second variable. Lyophilised peptide is stable for extended periods at −20°C, protected from light. Reconstituted solution is a different material entirely: held at 2–8°C, vulnerable to freeze-thaw cycling, oxidation at methionine and cysteine residues, and adsorption onto container surfaces at low concentrations. Temperature excursions don't announce themselves. A denatured peptide looks identical in the vial.
Every lot we release carries batch-specific HPLC and mass spectrometry documentation for exactly this reason, and our small-batch synthesis exists to keep sequence fidelity tight rather than to fill a marketing bullet.
One boundary, stated plainly: these compounds are supplied for laboratory research use only and are not for human or veterinary consumption. Questions concerning an animal belong with a licensed veterinarian, and questions concerning a person belong with a licensed physician.
Best Peptides for Fat Loss: Research Compound Comparison
The table compares the five compounds most frequently studied in this space by mechanism, evidence depth, and handling demand. Evidence depth is the column that should drive study design, and it's the one vendor charts routinely omit.
| Compound | Mechanism class | Depth of published evidence | Handling and stability notes | Professional assessment |
|---|---|---|---|---|
| Tesamorelin | GHRH analogue acting on pituitary somatotrophs | Randomised placebo-controlled human trials in one narrow clinical population, reporting visceral adipose tissue reduction | Lyophilised, stored frozen and protected from light; solution stability is the limiting factor after reconstitution | The only compound here with a genuine randomised human file, which makes it the reference point rather than the trend |
| AOD-9604 | C-terminal hGH fragment (amino acids 177–191) acting directly on adipocytes | Strong rodent lipolysis data; the larger human obesity trial did not separate from placebo on weight endpoints | Short sequence, generally robust as a lyophilised powder under standard frozen storage | Mechanistically interesting and clinically underwhelming, which is exactly how it should be described |
| Modified GRF 1-29 (CJC-1295 no DAC) | GHRH analogue with reported half-life near 30 minutes | Pharmacodynamic data on growth hormone and IGF-1 release; body-composition endpoints are thin | Pulse kinetics mean timing sensitivity in study design; standard frozen lyophilised storage | Useful for studying pulsatile growth hormone release, not for claiming a fat-loss outcome |
| Ipamorelin | Selective GHS-R1a (ghrelin receptor) pentapeptide agonist | Preclinical selectivity data showing limited cortisol and prolactin effect; human fat-loss data absent | Very short sequence with good lyophilised stability; still degrades in solution | Frequently paired with a GHRH analogue in research models, which complicates attributing any observed effect |
| 5-Amino-1MQ | NNMT inhibitor, small molecule rather than a peptide | Preclinical rodent data reporting reduced fat mass in diet-induced obesity models | Small molecule handling differs from peptides; confirm identity and purity documentation separately | Promising early mechanism, zero human trial data, and it does not belong on a peptide ranking at all |
What If: Research Material Scenarios
What if a vial arrives at room temperature after shipping?
Check the certificate and the physical state of the cake before assuming the lot is compromised. Lyophilised peptide tolerates short ambient excursions far better than solution does, because water is what enables hydrolysis and aggregation. The risk is cumulative rather than binary, so a single transit excursion on dry powder is a different problem from a cooler failure on a reconstituted vial. Document the exposure, because it belongs in the record if downstream results look inconsistent.
What if the certificate lists purity but no net peptide content?
Treat the milligram figure on the label as gross fill weight and request the peptide content assay. Purity by HPLC describes the proportion of correct sequence within the peptide present, not how much peptide the vial holds. Without both numbers, concentration calculations carry an unknown error that propagates through every result. Any supplier running proper analytics can produce that figure on request.
What if the lyophilised cake looks collapsed, filmy, or unusually small?
Photograph it, record the lot number, and contact the supplier before reconstituting anything. Cake collapse often points to a lyophilisation or moisture issue rather than degradation of the sequence itself, but appearance alone cannot distinguish the two. Small fill masses legitimately look like a thin film at the base of the vial, which is why documentation matters more than visual inspection.
What if a compound is marketed as a research alternative to GLP-1 drugs?
Read that framing as a marketing claim rather than a scientific one. Semaglutide and tirzepatide are incretin receptor agonists with large randomised human trial programmes behind them, and none of the compounds discussed here act through GLP-1 or GIP receptors or carry comparable clinical evidence. Comparing a rodent-stage NNMT inhibitor to an incretin drug conflates mechanism with outcome, and no honest supplier should be doing it.
The Unglamorous Truth About Fat-Loss Peptide Marketing
Here's the honest answer: no compound in this category has human evidence remotely comparable to the incretin drugs, and vendors ranking the best peptides for fat loss by potency are ranking copywriting. Tesamorelin has real randomised data in one narrow clinical population. AOD-9604 failed its larger human test. MOTS-c and 5-Amino-1MQ are preclinical compounds with genuinely interesting mechanisms and no human body-composition trials worth citing. That's the state of play in 2026. Anyone presenting it with more certainty is selling confidence the literature hasn't produced yet.
If you're evaluating material for a study, our batch-specific certificates of analysis show HPLC and mass spectrometry data for each lot, the full research catalog lists sequences and presentations, common handling and documentation questions are answered in our peptide FAQ, and company and sourcing information covers how we synthesise and ship.
Choosing among the best peptides for fat loss is less a ranking exercise than a matching exercise, pairing a mechanism with a model that can actually measure it. The compounds with the boldest rodent fat-mass figures tend to be the ones furthest from a human endpoint, while the ones carrying real clinical files are narrow, specific, and comparatively boring. That gap between mechanistic promise and translated outcome is the whole story of this category. It's also the only place careful research still has something genuinely new to contribute.
Build a pack
Researching more than one compound?
Build a multi-vial pack and the discount applies automatically as you add doses.
Questions
RESEARCH USE ONLY · NOT EVALUATED BY THE FDA